The combination of erlotinib and gemcitabine is a recognized option for patients with metastatic pancreatic cancer whose common adverse events such as skin rash, diarrhea, or fatigue are usually easily manageable. Interstitial lung disease (ILD) is a life-threatening toxicity reported in patients with non-small-cell lung cancers treated with epidermal growth factor receptor-tyrosine kinase inhibitors or gemcitabine. This side effect is extremely rare in patients with pancreatic cancer. We report fatal treatment-related ILD that occurred in a 67-year-old patient with metastatic pancreatic cancer. Risk factors and pathophysiology of ILD need further investigation but caution is highly recommended for patients with an underlying pulmonary disease when using erlotinib in monotherapy or combination therapy.
SteinsM., ThomasM., GeißlerM.Erlotinib: recent results. Cancer Res.2014; 201: 109–123.
2.
MooreM.J., GoldsteinD., HammJ.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.2007; 25(15): 1960–1966.
3.
UmemuraS., YamaneH., SuwakiT.Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol.2011; 137(10): 1469–1475.
4.
LaiY.C., LinP.C., LaiJ.I.Successful treatment of erlotinibinduced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Int J Clin Pharmacol Ther.2011; 49(7): 461–466.
NagariaN.C., CogswellJ., ChoeJ.K., KasimisB.Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol.2005; 23(10): 2423–2424.
8.
ChangS.C., ChangC.Y., ChangS.J.Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Clin Lung Cancer.2013; 14(1): 55–61.
9.
KudohS., KatoH., NishiwakiY.; Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med.2008; 177(12): 1348–1357.
10.
YonedaK.Y., SheltonD.K., BeckettL.A., GandaraD.R.Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol.2007; 2(6): 537–543.
11.
BoeckS., HausmannA., ReibkeR., SchulzC., HeinemannV.Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs.2007; 18(9): 1109–1111.
12.
TamiyaA., EndoM., ShukuyaT.Features of gemcitabinerelated severe pulmonary toxicity: patients with pancreatic or biliary tract cancer. Pancreas.2009; 38(7): 838–840.
13.
MatsunoO.Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res.2012; 13(1): 39.
14.
CharpidouA.G., GkiozosI., TsimpoukisS.Therapy-induced toxicity of the lungs: an overview. Anticancer Res.2009; 29(2): 631–639.
15.
BoeckS., HausmannA., ReibkeR., SchulzC., HeinemannV.Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs.2007; 18(9): 1109–1111.
16.
LiuV., WhiteD.A., ZakowskiM.F.Pulmonary toxicity associated with erlotinib. Chest.2007; 132(3): 1042–1044.
17.
CorvolH., FlameinF., EpaudR., ClementA., GuillotL.Lung alveolar epithelium and interstitial lung disease. Int J Biochem Cell Biol.2009; 41(8-9): 1643–1651.
18.
WillisB.C., BorokZ.TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol.2007; 293(3): L525–L534.
19.
SuzukiH., AoshibaK., YokohoriN., NagaiA.Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res.2003; 63(16): 5054–5059.
20.
RyuJ.H., DanielsC.E., HartmanT.E., YiE.S.Diagnosis of interstitial lung diseases. Mayo Clin Proc.2007; 82(8): 976–986.
21.
EshuisM., AhsmannE.J., van EgmondN.H.Fatal interstitial lung disease associated with erlotinib use. Ned Tijdschr Geneeskd.2013; 157(7): A5519.
22.
RenS., LiY., LiW.Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration.2012; 84(5): 431–5.
23.
ter HeineR., van den BoschR.T., Schaefer-ProkopC.M.Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer.2012; 75(3): 391–7.
24.
TianQ., ChenL.A.Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease. Case Rep Oncol.2011; 4(3): 464–466.
25.
KuoL.C., LinP.C., WangK.F., YuanM.K., ChangS.C.Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Med Oncol.2011; 28(1): 79–82.
AoeK., HirakiA., MurakamiT.Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy. Anticancer Res.2005; 25(1B): 415.
28.
TakedaM., OkamotoI., MakimuraC., FukuokaM., NakagawaK.Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol.2010; 5(7): 1103–4.
29.
TsubataY., HamadaA., SutaniA., IsobeT.Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther.2012; 8(1): 154–6.
